Moventig (Naloxegol)

Naloxegol, the active ingredient in Moventig, is a µ‑opioid receptor antagonist presented as an oral dosage form for oral administration. It selectively blocks peripheral µ‑opioid receptors, thereby counteracting the gastrointestinal motility inhibition caused by opioid analgesics and is used to treat opioid‑induced constipation in patients on chronic opioid therapy.

GNH USA supplies Moventig as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing products that meet EU regulatory standards and ensuring consistent quality across global markets.

Moventig (naloxegol) is used to manage opioid‑induced constipation, a condition resulting from opioid‑mediated reduction of gastrointestinal motility.

Opioid‑induced constipation: improves bowel movement frequency and reduces stool hardness in patients receiving opioid analgesics.

Naloxegol may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Abdominal pain - Diarrhea - Nausea - Flatulence

Serious or Rare Side Effects: - Intestinal obstruction - Severe abdominal pain - Allergic reactions (e.g., rash, angioedema) - Pancreatitis

When prescribing Moventig, clinicians should consider several safety precautions to minimize risk.

Assess bowel function before initiating therapy: confirm absence of existing obstruction. Monitor for abdominal pain or bloating: discontinue if severe symptoms develop. Avoid use in patients with known or suspected gastrointestinal obstruction. Use caution in severe hepatic impairment: adjust therapy based on clinical judgment. Adjust dose in renal impairment: consider reduced exposure in patients with creatinine clearance <30 mL/min. Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Naloxegol interacts with several drug classes that can alter its exposure or efficacy.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase naloxegol concentrations and risk of toxicity. - Concomitant use with other opioid antagonists (e.g., methylnaltrexone): may reduce therapeutic effect on constipation. - Known or suspected bowel obstruction: co‑administration can exacerbate condition.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin, fluconazole): may modestly increase exposure, requiring clinical monitoring. - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce naloxegol levels, potentially decreasing efficacy.